Rapport Therapeutics (RAPP)

Executive Summary

Rapport Therapeutics is a clinical-stage biopharmaceutical company pioneering precision medicines for neurological disorders by targeting receptor-associated proteins (RAPs). Its lead candidate, RAP-219, is a positive allosteric modulator of AMPA receptors designed to treat focal epilepsy and other seizure disorders with improved selectivity and reduced side effects. The company completed a Phase 1/2 trial in focal onset seizures in September 2025 and is currently enrolling two Phase 2 trials: one for refractory focal epilepsy (expected completion 2028) and another for bipolar I disorder (expected completion end of 2026). With a strong scientific foundation and a novel mechanism targeting neural circuit-specific proteins, Rapport aims to address significant unmet needs in treatment-resistant epilepsy and mood disorders. The company went public in May 2024, raising capital to advance its pipeline. While early-stage, the potential for RAP-219 to differentiate from standard-of-care therapies positions Rapport as a compelling player in neurology.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 Topline Data for RAP-219 in Bipolar I Disorder40% success
• H2 2027Phase 2 Interim Data for RAP-219 in Refractory Focal Epilepsy35% success
• H1 2027Initiation of Phase 2 Trial for RAP-219 in Treatment-Resistant Epilepsy (Additional Indication)50% success